Corona Remedies IPO Date 2026, Price, GMP, Reviews, Details
Corona Remedies Pvt Ltd is a major Indian pharmaceutical corporation that has a great footprint in the healthcare sector, and its IPO will be coming up in December 2025. Corona Remedies IPO Date 8th December 2025 Corona Remedies IPO price band 1008-1062/share.
The size of the issue is approximately 655 crore, and the Corona remedies IPO GMP (Grey Market Premium) is trading at 300-365 indicating that there is good interest shown by the investor. As the pharma industry is in good health with a good turnover and continuous growth, Corona Remedies Pvt Ltd intends to consolidate its position in the market by such public issues.
This blog breaks down everything you need to know: from IPO dates, price band, GMP, financial performance, subscription guidance, broker sentiment and a detailed view on whether you should consider applying.
Corona Remedies IPO - Basic Details
Particular | Detail |
Company Name | Corona Remedies Ltd |
Industry | Pharmaceuticals (Branded Formulations) |
IPO Type | Book-Built Issue (OFS Only) |
Issue Size | ₹655.37 crore |
Corona Remedies IPO Date (Open) | December 8, 2025 |
Corona Remedies IPO Date (Close) | December 10, 2025 |
Face Value | ₹10 per share |
Corona Remedies IPO Price | ₹1,008 to ₹1,062 per share |
Lot Size | 14 shares |
Minimum Retail Investment | ₹14,868 |
Listing Exchange | NSE & BSE |
Tentative Allotment Date | December 11, 2025 |
Tentative Listing Date | December 15, 2025 |
This table captures all essential issue details including Corona Remedies IPO price, lot size, and listing timelines.
Overview
Corona remedies Ltd is a pharmaceutical company whose main emphasis is on developing, producing and marketing branded prescription formulations. The company has operations in a few key therapeutic segments that include women’s health, respiratory, gastrointestinal, cardiology, diabetes management, dermatology, pain management, nutraceuticals, paediatrics and others.
Its multi-therapy and multi-brand strategy is what makes Corona Remedies stand out of the bulk of its competitors. The company has a portfolio of almost 70-80 brands and has not tied itself to one or two blockbuster drugs, which have guaranteed a range of revenue streams. This minimizes risk and the earnings profile is more predictable.
The company has two manufacturing plants (one in Gujarat, and one in Himachal Pradesh) that are in line with the current regulatory standards. This gives Corona Remedies adequate capacity to support scale expansion and ensures supply reliability. The Corona Remedies IPO comes at a time when India’s drug market is experiencing deeper penetration of branded generics, increased demand for chronic therapy lines, and rising healthcare consumption across Tier-2 and Tier-3 cities.
While the IPO is entirely an Offer for Sale (OFS), meaning no fresh funds flow into the company, it still offers retail investors a chance to participate in a company that has recorded notable growth in turnover, brand penetration, and therapeutic coverage.
Financial Position (Elaborated & Deep Breakdown)
To understand whether the Corona Remedies IPO merits investor interest, looking at the company’s financial strength is essential. Instead of just glancing at the top line, it helps to examine the deeper components of the company’s performance.
Revenue Growth & Corona Remedies Turnover
Corona Remedies has delivered consistent growth in turnover over the years. The company’s revenue has crossed the ₹1,100 crore mark, reflecting expansion across multiple therapeutic verticals.
The growth appears to stem from:
- Increased penetration of existing brands
- Launch of new formulations in chronic therapies
- Expansion of distribution reach into smaller towns
- Increased medical representative network
- Scale-up of flagship brands in gastro, respiratory, and women’s health
The company’s turnover trend suggests that Corona Remedies has been steadily gaining market presence in the branded generics space-an area known for stable demand.
Profitability Profile
Pharma manufacturing typically offers decent margins, particularly for companies focused on branded generics rather than pure contract manufacturing.
Corona Remedies has been seeing:
- Healthy operating margins supported by scale
- Steady EBITDA margin expansion driven by product mix improvement
- A favourable chronic-to-acute therapy ratio
- Benefits of its in-house manufacturing capabilities
While margins can fluctuate due to raw material price swings or regulatory pressures, the company’s product mix (spread across multiple therapies) cushions it from sharp shocks.
Corona Remedies IPO Price Structure & Operational Efficiency
A deeper look at the cost structure reveals:
- Raw material expenses are significant due to excipients, APIs, and packaging materials
- Employee expenses are rising but aligned with expansion in the field force
- Marketing and distribution spending is a major element, typical for branded formulations
- Manufacturing costs have benefited from economies of scale
The company’s shift toward chronic segments (which require sustained prescriptions) helps improve stability of earnings.
Balance Sheet Health
Corona Remedies has maintained a controlled level of debt, which supports long-term stability. The company’s asset base-especially manufacturing plants-is modern and scalable. Working capital management appears reasonably tight, which is essential in pharma distribution cycles.
Overall, the financial picture reflects a company with:
- Strong turnover growth
- Healthy profitability
- Robust operations
- Solid distribution footprint
This financial resilience is one reason the IPO has attracted considerable investor interest.
What to See Before Applying? (GMP + Subscription Rule)
Retail investors looking for clarity should focus on two indicators during the IPO window:
1. Corona Remedies IPO GMP (Grey Market Premium)
The Corona Remedies IPO GMP has shown a strong upward trend, indicating favourable sentiment. A stable or rising GMP on the last day usually signals high demand and the possibility of positive listing performance.
Simple Decision Rule Many Investors Use:
- If GMP is above ₹20 on the final day – Apply
- If GMP is flat or weak – Avoid listing-gain attempt
Corona Remedies currently shows a GMP far stronger than typical mid-sized pharma IPOs, which is why traders remain optimistic.
2. Subscription Data
Subscription figures provide insight into market appetite.
- High QIB subscription signals institutional confidence
- Strong NII subscription indicates trader interest
- Healthy Retail subscription confirms broad participation
For safer entry, check subscription numbers on the last day before applying.
When Should You Apply?
The best time to apply is on the last day of the IPO window.
This approach helps because:
- GMP becomes more accurate
- Subscription data across segments is visible
- You avoid applying based on early hype
- Sentiment stabilizes and becomes predictable
Applying early rarely offers an advantage. Waiting until the last day gives you the maximum amount of actionable information.
How to Check IPO Allotment Status?
Once the IPO closes and allotment is processed, investors can check status in the following way:
- Visit the IPO registrar’s official allotment page
- Enter PAN, application number or DP ID
- Submit to view your allotment status
- If allotted, shares appear in the demat account before listing
- If not allotted, the blocked amount is automatically released under ASBA
The allotment for Corona Remedies is expected on December 11, with listing expected on December 15.
Big Broker View
Analyst views on Corona Remedies IPO are generally constructive:
Positives Highlighted
- Strong turnover growth and diversified product portfolio
- Two compliant manufacturing facilities
- Presence across high-demand chronic and acute therapies
- Proven brand-building capability in prescription markets
- Well-established national sales and distribution network
Risks Highlighted
- Entirely OFS issue; company gets no fresh capital
- Pricing controls and regulatory pressures in pharma
- Raw-material cost fluctuations may impact margins
- Premium valuations at the upper end of price band
Overall sentiment: Subscribe for long-term, especially for investors looking to add a mid-size pharma formulation player to their portfolio.
Conclusion
The Corona Remedies Pvt Ltd public issue shows strong potential for long-term growth in the healthcare sector. With an attractive Corona Remedies IPO price, a solid Corona Remedies turnover, and positive sentiment reflected in the Corona Remedies IPO GMP, the company is gaining investor confidence. It can be regarded as a huge opportunity as the Corona Remedies IPO date approaches, and anyone willing to invest in a financially stable and developing pharmaceutical brand would take this chance.
The Corona Remedies IPO comes at the time when the pharma industry in India is on a strong growth path. The company has an attractive long-term story with high turnover, diversified brands, pan-India distribution and scalable manufacturing capacity.
In the case of listing gains, there should be monitoring of GMP and subscription data. To invest in the long run, the fundamentals provide stability and the upsurge potential. To balance it out, monitor the end-of-day GMP and implement in case sentiment is high.
Disclaimer
This article is for educational purposes only. It is not investment advice. Stocks are volatile and the activities of the company can impact the prices in the short-term. Before investors make decisions, they should carry out independent research or seek the advice of a financial advisor.
FAQ'S
What is the Corona Remedies IPO date?
The IPO opens on December 8, 2025 and closes on December 10, 2025.
What is the Corona Remedies IPO price band?
The price band is ₹1,008 to ₹1,062 per share.
What is the Corona Remedies IPO GMP?
The grey market premium has shown strong traction, indicating potential listing-day interest. Final GMP on the last day should be used to make a decision.
What is the turnover of Corona Remedies Pvt Ltd?
Corona Remedies turnover has crossed ₹1,100+ crore, driven by expansion across multiple therapeutic areas and strong brand penetration.
Should I apply for the Corona Remedies IPO?
Apply only after checking final-day GMP and subscription data. For long-term investors, the diversified pharma business model offers stability and growth potential.
